US 12,466,839 B2
Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia
Damien Picard, Basel (CH); and Pierre Saint-Mezard, Basel (CH)
Assigned to Vaderis Therapeutics AG, Basel (CH)
Appl. No. 18/247,261
Filed by VADERIS THERAPEUTICS AG, Basel (CH)
PCT Filed Sep. 29, 2021, PCT No. PCT/EP2021/076811
§ 371(c)(1), (2) Date Mar. 29, 2023,
PCT Pub. No. WO2022/069552, PCT Pub. Date Apr. 7, 2022.
Claims priority of application No. 2015536 (GB), filed on Sep. 30, 2020.
Prior Publication US 2024/0092801 A1, Mar. 21, 2024
Int. Cl. C07D 498/04 (2006.01); A61K 31/536 (2006.01); A61P 9/00 (2006.01)
CPC C07D 498/04 (2013.01) [A61P 9/00 (2018.01); A61K 31/536 (2013.01)] 36 Claims
 
1. A method of treating Hereditary Hemorrhagic Telangiectasia (HHT) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

OG Complex Work Unit Chemistry